July 18, 2019
IAS 2019 is just ahead, July 21-24 in Mexico City. To help you prepare, read on for a round-up of research and happenings you won’t want to miss, a roadmap to guide you to sessions where HIV prevention is center stage, and how to follow on-site or from afar.
This year’s conference will feature data from late-breakers on highly anticipated research including:
- Data on the first-ever human trial of a new PrEP implant
- Analysis of the need to integrate HIV prevention with sexual & reproductive health in light of the ECHO study results
- Updates from the Discover trial of F/TAF for PrEP
- Findings from a study of same-day PrEP initiation among gay men and other men who have sex with men
- Data from the ASCENT study evaluating an HIV mosaic vaccine
For the full conference program go to the website for IAS 2019, and find your optimal schedule for following HIV prevention with AVAC’s conference roadmap, which can be sorted by timing, intervention or session type (Excel/PDF here).
Consider adding these satellite and conference events below, some hosted by AVAC and partners, to your calendar!
- “Sticky Linkage”: Latest evidence and new strategies
Sunday 21 July, 8:00-10:00, Palacio de Iturbide 1 y 2This session on approaches for improving ART initiation and retention will talk about challenges to the idea that the continuum of care is linear. The agenda includes the results of segmentation research aimed at improving linkage to treatment among South African men.
- Hormonal contraception and HIV risk: Understanding the ECHO trials results, and what’s next for women, providers, policies, and programmes
Sunday 21 July, 17:00-19:00, Palacio de Valparaíso 2Come to this forum to hear a review of the ECHO study results and discussion of their implications for women, providers, policies and programs. Presentations will focus on informed choice for women, the need to expand method mix, and the importance of integrating HIV prevention with sexual and reproductive health.
- An HIV vaccine to prevent HIV acquisition
Sunday 21 July, 17:00-19:00, Palacio de Valparaíso 1Learn more about the newest candidate for a vaccine to be investigated in a trial known as Mosaico. This session will provide an overview of pre-clinical work and next steps for the latest mosaic vaccine strategy.
- Data from six locations inform the future of the HIV response
Monday 22 July, 14:15-15:00This press conference will unveil a new analysis from amfAR, AVAC and Friends of the Global Fight of six case studies of progress toward epidemic control. From the report Translating Progress Into Success to End the AIDS Epidemic, the analysis identifies elements that accelerate the impact of treatment and prevention with implications for program, policy, implementation and advocacy. The press conference will only be open to journalists, but you can watch the livestream and watch for a future Advocates Network with links to the report post-launch.
- Improving prevention choice, while we wait for an HIV vaccine: Prioritizing resources for key population-specific prevention research and implementation
Tuesday 23 July, 14:30-16:00, Palacio de Valparaíso 1For a broad analysis of improving prevention for key populations, check out this presentation, part of a larger session titled, Prevention is more than PrEP.
- High adherence and sustained impact on HIV-1 incidence: Final results of an open-label extension trial of the dapivirine vaginal ring
Tuesday 23 July, 14:30-16:00, Palacio de Valparaíso 2Catch the latest results on the effectiveness of the dapivirine vaginal ring at this session on the findings of the HOPE open-label study.
Following from afar?
AVAC will offer comments and updates on Twitter and Facebook. Use the conference hashtag — #IAS2019.
Get the latest news on the conference at this dedicated page on the IAS 2019 website.
Interested in the events where AVAC is participating? Click here. And watch this space for additional updates.